StevenPLaRosaMD

PubMed

• 3 citations
  Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin.
  Melanie Gooldy, Christelle M Roux, Steven P LaRosa, Nicole Spaulding, Charles J Fisher Jr> ;Plos One. 2022 Jan 1
• 7 citations
  Removal of COVID-19 Spike Protein, Whole Virus, Exosomes, and Exosomal MicroRNAs by the Hemopurifier® Lectin-Affinity Cartridge in Critically Ill Patients With COVID-1...
  Dennis E. Amundson, Usman S. Shah, Rosalia de Necochea-Campion, Michael T. Jacobs, Steven P. LaRosa, Charles J. Fisher> ;Frontiers in Medicine. 2021 Oct 8
• 2 citations
  Time for Well-Powered Controlled Prospective Studies to Test a Causal Role for Herpes Viruses in Alzheimer's Disease Using Antiherpetic Drugs.
  Pascal J. Goldschmidt-Clermont, Fred G Volinsky, Steven P LaRosa, John R. Gilbert, Margaret A. Pericak-Vance> ;The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2020 May 22
• 157 citations
  Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials.
  Sachin Yende, Shamly Austin, Andrew Rhodes, Simon Finfer, Steven M. Opal, Taylor Thompson, Fernando A. Bozza, Steven P. LaRosa, V. Marco Ranieri, Derek C. Angus> ;Critical Care Medicine. 2016 Aug 1
• 31 citations
  Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from Blood by Heparin-Functional Hemoperfusion Media
  Keith Mccrea, Robert Ward, Steven P. LaRosa> ;Plos One. 2014 Dec 3
• 60 citations
  Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or se...
  Gordon R. Bernard, Bruno Francois, Jean-Paul Mira, Jean Louis Vincent, R. Phillip Dellinger, James A. Russell, Steven P. LaRosa, Pierre-François Laterre, Mitchell M. L...> ;Critical Care Medicine. 2014 Mar 1
• 217 citations
  A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients wi...
  Jean Louis Vincent, Mayakonda K. Ramesh, David Ernest, Steven P. LaRosa, Jan Pachl, Naoki Aikawa, Eric Hoste, Howard Levy, Joe Hirman, Marcel Levi, Mradul Kumar Daga, ...> ;Critical Care Medicine. 2013 Sep 1
• 11 citations
  Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?
  Steven M. Opal, Steven P. LaRosa> ;American Journal of Respiratory and Critical Care Medicine. 2013 May 15
• 556 citations
  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
  Steven M. Opal, Pierre-François Laterre, Bruno François, Steven P. LaRosa, Derek C. Angus, Jean-Paul Mira, Xavier Wittebole, Thierry Dugernier, Dominique Perrotin, Mar...> ;JAMA. 2013 Mar 20
• Drotrecogin alfa (activated) in severe sepsis--authors' reply.
  Andre C. Kalil, Steven P. LaRosa> ;The Lancet. Infectious Diseases. 2013 Feb 1
• 84 citations
  White paper: Recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug...
  Brad Spellberg, Eric P. Brass, John S. Bradley, Roger J. Lewis, David M. Shlaes, Paul G. Ambrose, Anita Das, Helen W. Boucher, Yohei Doi, John G. Bartlett, Robert A. B...> ;Clinical Infectious Diseases. 2012 Oct 15
• 6 citations
  Clinical and laboratory diagnosis of central nervous system histoplasmosis.
  Sangeetha Ranganath, Travea A. McGhie, Steven LaRosa, Weston Lehman, Robert Fader> ;The American Journal of Medicine. 2012 Oct 1
• 59 citations
  Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression
  Andre C. Kalil, Steven P. LaRosa> ;The Lancet. Infectious Diseases. 2012 Sep 1
• 7 citations
  Immune Aspects of Sepsis and Hope for New Therapeutics
  Steven P. LaRosa, Steven M. Opal> ;Current Infectious Disease Reports. 2012 Aug 1
• 31 citations
  Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.
  Andre C. Kalil, Steven P. LaRosa, Jagadish Gogate, Melvyn Lynn, Steven M. Opal> ;Shock. 2011 Oct 1
• 78 citations
  Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia : a randomized trial.
  Richard G. Wunderink, Pierre-François Laterre, Bruno François, Dominique Perrotin, Antonio Artigas, Luis Otero Vidal, Suzana Margareth Lobo, Jorge San Juan, Sung Chul ...> ;American Journal of Respiratory and Critical Care Medicine. 2011 Jun 1
• 26 citations
  Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
  Mark Tidswell, Steven P. LaRosa> ;Expert Review of Anti-Infective Therapy. 2011 May 1
• 13 citations
  Biomarkers: the future.
  Steven P. LaRosa, Steven M. Opal> ;Critical Care Clinics. 2011 Apr 1
• 2 citations
  Activated protein C for H1N1 influenza? More work to do!
  Steven P. LaRosa> ;Critical Care. 2010 May 18
• 167 citations
  Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
  Mark Tidswell, William Tillis, Steven P. LaRosa, Melvyn Lynn, AE Wittek, Richard Kao, Janice L. Wheeler, Jagadish Gogate, Steven M. Opal> ;Critical Care Medicine. 2010 Jan 1
• 5 citations
  Year in review 2008: Critical Care--sepsis.
  Steven M. Opal, Steven P. LaRosa> ;Critical Care. 2009 Oct 21
• 38 citations
  A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia.
  Pierre-François Laterre, Steven M. Opal, Edward Abraham, Steven P. LaRosa, Abla A. Creasey, Fang Xie, Lona Poole, Richard G. Wunderink> ;Critical Care. 2009 Mar 15
• At the heart of the matter.
  Marisa Holubar, Michael J. Connor, Steven P. LaRosa, Arun Singh> ;The American Journal of Medicine. 2009 Apr 1
• 23 citations
  Sepsis Strategies in Development
  Steven P. LaRosa, Steven M. Opal> ;Clinics in Chest Medicine. 2008 Dec 1
• 8 citations
  Use of corticosteroids in the sepsis syndrome: what do we know now?
  Steven P. LaRosa> ;Cleveland Clinic Journal of Medicine. 2005 Dec 1
• Join now to see all

Journal Articles

•  
  Bernard GR, Francois B, Mira JP,Vincent JL, Dellinger RP, Russell JA, et al., Crit Care Med, 1/1/2014
• A Controlled Clinical Trial of Eritoran, an Antagonist of MD2-TLR4, in Patients with Severe Sepsis: THE ACCESS TRIAL  
  Opal SM, Laterre PF, Francois B, et al., JAMA, 1/1/2013
• A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients wi...  
  Vincent JL, Ramesh M, Ernest D, Crit Care Med, 1/1/2013
• Recombinant Human Activated Protein C as a Therapy for Severe Sepsis: Lessons Learned?  
  Opal SM, LaRosa SP, Am J Respir Crit Care Med, 1/1/2013
• Real-Life Experience with Drotrecogin Alfa (Activated) for Severe Sepsis: An Effectiveness and Safety Meta-analysis and Meta-regression  
  Kalil AC, LaRosa SP, Lancet ID, 1/1/2012
• Immune Aspects of Sepsis and Hopes for new therapeutics  
  LaRosa SP, Opal SM, Curr Infect Dis Rep, 1/1/2012
• White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug...  
  LaRosa SP, Clin Infect Dis, 1/1/2012
• Sepsis Strategies – Old and New  
  LaRosa SP, Opal SM, Clin Invest, 1/1/2011
• Recombinant Tissue Factor Pathway Inhibitor in Severe Community-Acquired Pneumonia: A Randomized Trial  
  Wunderink RG, Laterre PF, François B, Perrotin D, Artigas A, Otero Vidal L, Lobo SM, San Juan J, Hwang SC, Dugernier T, et al., Am. J. Respir. Crit. Care Med, 1/1/2011
• Therapies for Severe Sepsis Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis  
  Kalil AC, Gogate J, Lynn M, Opal SM; the Eritoran Sepsis Study Group, Shock, 1/1/2011
• Phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis  
  Tidswell M, Tillis W, et al., Crit Care Med, 1/1/2010
• Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient  
  Chan PA, Connell NT, Gabonay AM, Westley B, Larkin JM, et al., Clin Microbiol Infect, 1/1/2010
• Diagnostic dilemma: The heart of the matter  
  Holubar M., Connor M., Singh A, Am J Med, 1/1/2009
• A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (Tifacogin) in patients with severe community-acquired pneumonia  
  Laterre PF, Opal SM, Abraham E, Creasey AA, Xie F, Poole L, Wunderink RG, Critical Care, 1/1/2009
• Year in Review 2008: Critical care sepsis  
  Opal SM, LaRosa SP, Critical Care, 1/1/2009
• A case of undiagnosed syphilis in a patient undergoing coronary artery bypass graft and aortic valve surgery  
  Soliman MM, Dorotta I, et al., Infect Dis Clin Pract, 1/1/2008
• Decreased protein C, protein S and antithrombin levels are predictive of poor outcome in gram-negative sepsis caused by Burkholderia pseudomallei  
  Opal SM, Utterback B, et al., Int J Infect Dis, 1/1/2006
• Drotrecogin alfa (activated) in severe sepsis[comment]  
  LaRosa SP, N Engl J Med, 1/1/2006
• What’s new in antibiotics?  
  Padmanabhan R, Tomecki KJ, Dermatol Clin, 1/1/2005
• Antibiotics: What’s new  
  LaRosa SP, Tomecki KJ, Cutis, 1/1/2004
• Clinical trials of novel anticoagulants for severe sepsis: A tale of three molecules  
  LaRosa SP, Opal SM, Adv Sepsis, 1/1/2004
• Tick-borne infections  
  Singh-Behl D, Tomecki KJ, Dermatol Clin, 1/1/2003
• The clinical evaluation committee in a large phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS)  
  Dhainaut JF, Laterre PF, et al., Crit Care Med, 1/1/2003
• Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplant ever be discontinued?  
  Gordon S, Kalmadi S, et al., Clin Infect Dis, 1/1/1999
• Join now to see all

Books/Book Chapters

• Cleveland Clinic Internal Medicine Case Reviews 
  Chapter: 59 year old diabetic man with a painful hand ulcer 
  Tabbarah K, Choueiri T, Tachopoulou O,Editors: Longworth DL, Stoller JK, Casey DM, Jewell JK.Lippincott, Williams and Wilkins, Philadelphia2003

Abstracts/Posters

• Removal of Cytomegalovirus from blood by Heparin-functional Hemoperfusion Media
  McCrea K, Ward R, 44th Critical Care Congress, Phoenix, AZ, 1/17/2015
• Real-Life Experience with Drotrecogin Alfa Activated for Severe Sepsis: An Effectiveness and Safety Meta-analysis
  Kalil AC, LaRosa SP, 40th Critical Care Congress, San Diego, CA, 1/15/2011
• Comparative Efficacy of Eritoran, a Toll-Like Receptor 4 Antagonist, in Patients with Severe Sepsis and Higher Risk of Mortality by Type of Causative Pathogen
  LaRosa SP, Tidswell MA, 40th Critical Care Congress, San Diego, CA, 1/15/2011
• Serum Procalcitonin and Prothrombin Fragment 1.2 in Severe CAP: Can Biomarkers Predict Survival Benefit in Tifacogin Patients?
  Opal S, Laterre PF, Wunderink R, Su G, Hua, Y, Mendelson M, 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Meeting the Infectious Diseases Society of America, Washington, DC, 1/25/2008
• Therapeutic Rationale for Tissue Factor Pathway Inhibitor (TFPI) for Severe Community Acquired Pneumonia CAP)
  Opal S, Wunderink R, Laterre PF, Creasey AA, Tobias J, 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, 1/30/2004
• Fungal Infections as an Important Cause of Severe Sepsis
  Garber GE, Opal SM, Maki DG, Focus on Fungal Infections 13, Maui, HI, 1/19/2003
• A pilot study to examine the presence of Cytomegalovirus viremia and its relationship with adrenal function in patients with acute refractory septic shock
  Starkey C, Yen-Lieberman B, Annane D, Bellisant E, Crit Care Med, 1/1/2003
• Effect of Baseline Protein C, Antithrombin and IL-6 Levels on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis
  Dhainaut JF, Fisher CJ, Yan SB, Bernard GR for the PROWESS Study Group, American Thoracic Society International Conference, San Francisco, CA, 1/18/2001
• Effect of Age on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis
  Ely EW, Helterbrand JD, Bernard GR for the PROWESS Study Group, American Thoracic Society International Conference, San Francisco, CA, 1/18/2001
• Baseline Characteristics of Patients enrolled in the Phase III trial of rhAPC in Severe Sepsis
  Vincent JL, Bellomo R, et al., The Society of Critical Care Medicine’s 30th Critical Care Congress, 1/1/2001
• The Efficacy and safety of Recombinant Human Activated Protein C for the Treatment of Patients with Severe Sepsis
  Bernard GR, Laterre PF, et al., The Society of Critical Care Medicine’s 30th Critical Care Congress, 1/1/2001
• Drotrecogin Alfa (Activated) Reduces Mortality in Patients with Severe Sepsis Irrespective of Bacterial Pathogen Classification
  Basson B, Dhainaut JF, Kimasewitz G, Opal SM, 41st International Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1/1/2001
• Decreased Protein C, Protein S and Antithrombin III Levels are Predictive of Poor Outcome in Gram-negative Sepsis caused by Burkholderia pseudomallei
  Opal SM, Utterback B, Yan B, Helterbrand J, Simpson AJ, White N, Fisher CJ, Crit Care, 1/1/2000
• Purpura Fulminans and S. Pneumoniae Sepsis with Severe Acquired Protein C Deficiency Successfully Treated with Recombinant Human Activated Protein C
  Smith K, Neal J, Winton E, Fisher C, XVII Congress of the Intl. Society on Thrombosis and Haemostasis, Washington, DC, 1/1/1999
• Pneumocystis carinii Pneumonia in Patients without AIDS
  Kalmadi S, Longworth D, Truesdell L, Fisher C, Cornish N, Gordon S, 34th Annual Meeting of the Infectious Diseases Society of America; 35th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, 1996; San Francisco, CA, 1997, 1/18/1997
• Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Ever Be Discontinued?
  Gordon S, Kalmadi S, Truesdell L, Avery R, Arroliga A, Longworth D, 34th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, 1/18/1996
• Join now to see all

Lectures

• A General Review of Procalcitonin and Utilization in De-escalating Antibiotics 
  Fatima Hospital, North Providence, RI - 1/6/2014
• Severe Sepsis 
  Beverly Hospital, Beverly, MA - 1/30/2013
• Procalcitonin: Pro/Con Debate 
  San Antonio, TX - 1/9/2012
• ACCESS Trial Results 
  Houston, TX - 1/6/2012
• Biomarkers for Sepsis: From Readily to Experimental 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/20/2011
• Antithrombotics for Sepsis 
  San Diego, CA - 1/18/2011
• The Sepsis Disease State 
  Scott and White Healthcare, Temple, TX - 1/5/2011
• The Future of Sepsis Clinical Research 
  Snyder Institute of Infection, Calgary, Canada - 1/5/2011
• Biomarkers for Sepsis 
  Miami, FL - 1/9/2010
• A 51-year-old female presents with fever and generalized fatigue 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/2/2010
• A 44-year-old woman with abdominal pain and lower extremity rash 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/22/2009
• C. Difficile 
  Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI - 1/17/2009
• Sepsis and Septic Shock 
  University of Rhode Island, Providence, RI - 1/16/2009
• Procalcitonin 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/25/2008
• Antibiotic Issues in the ICU 
  Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI - 1/6/2008
• A 56-year-old man with fever and recent travel 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/23/2007
• A 66-year-old man with six weeks of increasing abdominal girth 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/13/2007
• Purpura Fulminans 
  Cleveland, OH - 1/11/2007
• A 52-year-old man with fevers and chills 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/10/2007
• Sepsis, Severe Sepsis, and Septic Shock 
  Providence, RI - 1/9/2007
• TNF as a specific target in severe sepsis - Is the story over 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/29/2006
• Infections Related to Trauma 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/17/2006
• An 88-year-old man with CMML who presents with progressive weakness and fatigue 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/7/2006
• Current Management of Severe Sepsis and Septic Shock 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/12/2005
• A 58-year-old man with chest pain radiation to his back and new onset lower extremity weakness 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/12/2005
• Join now to see all

Other

• Sepsis 
  LaRosa SP, Opal SM, Scientific American Textbook of Medicine
  http://www.sciammedicine.com/sciammedicine/institutional/tableOfContent.action#
  1/1/2014